Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Ensuring medication adherence with direct oral anticoagulant drugs: lessons from adherence with vitamin K antagonists (VKAs).

Di Minno A, Spadarella G, Tufano A, Prisco D, Di Minno G.

Thromb Res. 2014 May;133(5):699-704. doi: 10.1016/j.thromres.2014.01.016. Epub 2014 Jan 18. Review.

PMID:
24525314
2.

Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.

Potpara TS, Polovina MM, Licina MM, Stojanovic RM, Prostran MS, Lip GY.

Adv Ther. 2012 Jun;29(6):491-507. doi: 10.1007/s12325-012-0026-8. Epub 2012 Jun 7. Review.

PMID:
22684583
3.

Direct oral anticoagulants and bleeding risk (in comparison to vitamin K antagonists and heparins), and the treatment of bleeding.

Palareti G.

Semin Hematol. 2014 Apr;51(2):102-11. doi: 10.1053/j.seminhematol.2014.02.002. Epub 2014 Feb 28. Review.

PMID:
24861794
4.

When the rubber meets the road: adherence and persistence with non-vitamin K antagonist oral anticoagulants and old oral anticoagulants in the real world-a problem or a myth ?

Suryanarayan D, Schulman S.

Semin Thromb Hemost. 2014 Nov;40(8):852-9. doi: 10.1055/s-0034-1395156. Epub 2014 Nov 10. Review.

PMID:
25384183
5.

Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.

Cheng JW, Barillari G.

J Clin Pharm Ther. 2014 Apr;39(2):118-35. doi: 10.1111/jcpt.12122. Epub 2014 Jan 3. Review.

PMID:
24383983
6.

[Oral anticoagulation for atrial fibrillation].

Antz M, Beauport J, Vocke W.

Herzschrittmacherther Elektrophysiol. 2014 Mar;25(1):3-11. doi: 10.1007/s00399-014-0304-z. Epub 2014 Feb 22. German.

PMID:
24562906
7.

Barriers to warfarin use for stroke prevention in patients with atrial fibrillation in Hong Kong.

Lee VW, Tam CS, Yan BP, Man Yu C, Yin Lam Y.

Clin Cardiol. 2013 Mar;36(3):166-71. doi: 10.1002/clc.22077. Epub 2012 Nov 14.

8.

Transitions of care in anticoagulation management for patients with atrial fibrillation.

Deitelzweig SB.

Hosp Pract (1995). 2012 Oct;40(4):20-7. doi: 10.3810/hp.2012.10.999.

PMID:
23299032
9.

Improving the use of direct oral anticoagulants in atrial fibrillation.

Di Minno G, Russolillo A, Gambacorta C, Di Minno A, Prisco D.

Eur J Intern Med. 2013 Jun;24(4):288-94. doi: 10.1016/j.ejim.2013.01.021. Epub 2013 Apr 8. Review.

PMID:
23579170
10.

Drug adherence in patients taking oral anticoagulation therapy.

Ewen S, Rettig-Ewen V, Mahfoud F, Böhm M, Laufs U.

Clin Res Cardiol. 2014 Mar;103(3):173-82. doi: 10.1007/s00392-013-0616-8. Epub 2013 Sep 3. Review.

PMID:
23999974
11.

New anticoagulants for stroke prophylaxis in atrial fibrillation: assessing the impact on medication adherence.

Kopecky S.

Am J Cardiovasc Drugs. 2012 Oct 1;12(5):287-94. doi: 10.2165/11634130-000000000-00000. Review.

PMID:
22946769
12.

Evolving Treatments for Arterial and Venous Thrombosis: Role of the Direct Oral Anticoagulants.

Chan NC, Eikelboom JW, Weitz JI.

Circ Res. 2016 Apr 29;118(9):1409-24. doi: 10.1161/CIRCRESAHA.116.306925. Review.

13.

Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).

Halperin JL, Hankey GJ, Wojdyla DM, Piccini JP, Lokhnygina Y, Patel MR, Breithardt G, Singer DE, Becker RC, Hacke W, Paolini JF, Nessel CC, Mahaffey KW, Califf RM, Fox KA; ROCKET AF Steering Committee and Investigators.

Circulation. 2014 Jul 8;130(2):138-46. doi: 10.1161/CIRCULATIONAHA.113.005008. Epub 2014 Jun 3.

14.

The evolution of oral anticoagulant therapy.

Dittus C, Ansell J.

Prim Care. 2013 Mar;40(1):109-34. doi: 10.1016/j.pop.2012.11.011. Epub 2012 Dec 27. Review.

PMID:
23402464
15.

[The use of direct oral anticoagulants (DOAC) in the treatment atrial fibrillation (AF) patients].

Lehto M, Mustonen P, Tierala I.

Duodecim. 2014;130(17):1709-17. Review. Finnish.

PMID:
25272782
16.

Age-dependency of prescribing patterns of oral anticoagulant drugs in Austria during 2011-2014.

Schuh T, Reichardt B, Finsterer J, Stöllberger C.

J Thromb Thrombolysis. 2016 Oct;42(3):447-51. doi: 10.1007/s11239-016-1380-1.

PMID:
27221106
17.

Anticoagulant prevention in patients with atrial fibrillation: alternatives to vitamin K antagonists.

Kozlowski D, Budrejko S, Raczak G, Rysz J, Banach M.

Curr Pharm Des. 2013;19(21):3816-26. Review.

PMID:
23286429
18.

EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary.

Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P.

Eur Heart J. 2013 Jul;34(27):2094-106. doi: 10.1093/eurheartj/eht134. Epub 2013 Apr 26.

PMID:
23625209
19.

Home-monitoring of oral anticoagulation vs. dabigatran. An indirect comparison.

Alonso-Coello P, Zhou Q, Guyatt G.

Thromb Haemost. 2012 Oct;108(4):647-53. Epub 2012 Aug 23. Review.

PMID:
22918481
20.

Development of a tool to identify patients' preference for vitamin K antagonist or direct oral anticoagulant therapy.

Zolfaghari S, Harenberg J, Froelich L, Wehling M, Weiss C.

Semin Thromb Hemost. 2014 Feb;40(1):121-8. doi: 10.1055/s-0033-1361940. Epub 2013 Dec 31.

PMID:
24381153

Supplemental Content

Support Center